Clinical Trials

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04578847 2020-10-08

READIT

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03515018 2018-05-22

HU

60 enrolled

Phase EARLY_PHASE1 Unknown

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03228303 2017-10-10

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03241199 2017-08-08

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

15 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02687425 2016-02-22

SESPI

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02317159 2014-12-15

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Phase 4 Unknown

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01400074 2014-01-13

RE-NICE

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00028847 2013-09-17

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Phase 1/2 Unknown

60 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01503502 2013-04-10

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

150 enrolled

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01221376 2013-03-26

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01227135 2011-11-30

Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

66 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00112775 2011-06-07

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00297570 2007-10-10

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00146913 2007-04-27

AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

30 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00327262 2006-06-20

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

240 enrolled